ONO-4641 + ONO-4641 + ONO-4641 + ONO-4641 placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Multiple Sclerosis

Conditions

Multiple Sclerosis

Trial Timeline

Mar 1, 2010 → Dec 1, 2011

NCT ID

NCT01081782

About ONO-4641 + ONO-4641 + ONO-4641 + ONO-4641 placebo

ONO-4641 + ONO-4641 + ONO-4641 + ONO-4641 placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01081782. Target conditions include Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Sclerosis were approved

Approved (20) Terminated (0) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved

✅TeclistamabJohnson & JohnsonApproved

✅BortezomibJohnson & JohnsonApproved

✅DaratumumabJohnson & JohnsonApproved

✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01081782	Phase 2	Completed	Mar 1, 2010	Dec 1, 2011	Multiple Sclerosis

Competing Products

20 competing products in Multiple Sclerosis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1195	Moderna	Phase 2	0
NEX-20A	Nanexa AB	Phase 1	23
mRNA-2736	Moderna	Phase 1	0
mRNA-2808	Moderna	Phase 2	0
Placebo + Pirtobrutinib	Eli Lilly	Phase 2	27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide	Eli Lilly	Phase 1/2	32
agenT-797	MiNK Therapeutics	Phase 1	19
Duloxetine Hydrochloride (HCI) + Placebo	Eli Lilly	Phase 3	40
Temferon	Genenta Science	Phase 1/2	14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)	Celltrion	Phase 3	47
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	47
CS-0777 tablets + CS-0777 tablets + CS-0777 tablets	Daiichi Sankyo	Phase 1	29
ASP7487, Velcade, Dexamethasone	Astellas Pharma	Phase 1/2	24
PHE885	Novartis	Phase 2	27
Mirabegron + Placebo	Astellas Pharma	Approved	43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo	Astellas Pharma	Approved	43
Denileukin Diftitox (Ontak)	Eisai	Phase 1	21
Palonosetron	Eisai	Phase 2	35
BIW-8962	Kyowa Kirin	Phase 1	21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)	Kyowa Kirin	Phase 2	35